Last edition
News about "pharmacokinetics "
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
Pharmacokinetics | 11/03/2026 | By News Bureau | 155
IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC
Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.
Pharmacokinetics | 02/03/2026 | By News Bureau
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Pharmacokinetics | 20/01/2026 | By News Bureau | 226
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Pharmacokinetics | 19/01/2026 | By News Bureau | 406
Just-Evotec Biologics Secures Gates Foundation Grant to Expand Global Access to Biotherapeutics
The funding will support ten new molecular design projects over three years, leveraging Just-Evotec Biologics’ J.MD computational platform to optimise monoclonal antibodies and other biologics, reduce development costs and improve access to affordable therapies for infectious diseases in low- and middle-income countries.
Pharmacokinetics | 12/01/2026 | By News Bureau | 119
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Pharmacokinetics | 11/11/2025 | By Dineshwori | 358
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Pharmacokinetics | 13/10/2025 | By Dineshwori | 261
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Pharmacokinetics | 11/10/2025 | By Dineshwori | 529
Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101
The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.
Pharmacokinetics | 15/09/2025 | By Dineshwori | 108
TUL Signs Exclusive License Deal with Novo Nordisk for UBT251
Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.
Pharmacokinetics | 25/03/2025 | By Aishwarya | 376
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy